CULEVIT RESEARCH and DEVELOPMENT PROGRAMIMMUNAL LTD is the owner of the patent on “medical compositions to be used in the prevention and treatment of tumor diseases and the procedures for their manufacturing”, based on the scientific invention of biochemist dr. Gyula Kulcsár. The primary goal of Immunal Kft., the company formed to develop the preparation manufactured based on this invention into a medicine within the framework of the Culevit Research and Development Program. The intended composition of such medicine:
Arginine, Phenylalanine, Histidine, Methionine, Tyrosine, Tryptophan, B2-vitamin, B6-vitamin, C-vitamin, Adenine, biotin, Malic acid.
It is evident from the theory of the inventor, dr. Gyula Kulcsár that the infusion product form would be the ideal one for the treatment of tumors. In the case of an infusion treatment there is no absorption loss, the product contains only the active substances and the main advantage is that this way a large dose can be administered over a longer period and so the amount of protective active substances can be maintained permanently at high level. Consequently, a large amount of tumor cells could be destroyed, and so the existing tumors in the growing phase could also be successfully treated without any adverse effects .
The will-be medicine is still in the development phase, was chemically stabilized in 2002 and can be manufactured in bulk since then. At present pre-clinical studies and animal experiments are underway with the infusion product to propose ideal treatment conditions, dosage, administration methods (phased, constant ) and treatment duration in addition to proving the product's safety and efficacy.
Further development plans
The development efforts continue to be concentrated on the future medicine product. First the steps required by the National Pharmaceutical Institute (OGYI) should be carried out and the registration process hast to be started. Main objective is to reach the phase where human application can start, and to reach this stage as soon as possible. At present the medicine used in animal studies should not be administered to humans, and we estimate that the human trials in compliance with the laws on medicine development will take place in two years' time, provided that the National Pharmaceutical Institute issues its permission for the conducting of human studies. We hope that after this phase the medicine can be registered and may then be administered to patients in a clinical environment.
